Schrödinger

Schrödinger, Inc. is a scientific software and biotechnology company based in New York City. Founded in 1990, it specializes in developing computational tools for drug discovery and materials science. The company is publicly traded on the Nasdaq under the ticker symbol SDGR and is part of the Russell 2000 and S&P 600 indices. Schrödinger offers a variety of software tools that simulate and model molecular behavior at the atomic level. These include molecular dynamics simulations, free energy calculations, quantum mechanics calculations, and virtual screening tools. The flagship software, Maestro, has been instrumental in advancing research since its release in 1995. In addition to software, Schrödinger provides consulting services and collaborates with industry partners to enhance drug discovery efforts. The company also engages in drug development, targeting diseases such as non-Hodgkin's lymphoma and neurological disorders. With a revenue of $217 million in 2023 and a global workforce of over 1,015 employees, Schrödinger operates in multiple countries, including the US, Germany, Japan, and China. The leadership team, led by President and CEO Ramy Farid, is dedicated to advancing computational chemistry and drug discovery.